RDHL RedHill Biopharma Ltd. Stock Quote

RDHL [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

Index	-	P/E	-	EPS (ttm)	-2.12	Insider Own	0.22%	Shs Outstand	42.96M	Perf Week	3.54%
Market Cap	339.72M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	0.00%	Shs Float	34.99M	Perf Month	19.80%
Income	-81.90M	PEG	-	EPS next Q	-0.12	Inst Own	25.30%	Short Float	5.65%	Perf Quarter	-7.34%
Sales	83.90M	P/S	4.05	EPS this Y	-46.80%	Inst Trans	34.07%	Short Ratio	6.78	Perf Half Y	-13.06%
Book/sh	1.23	P/B	5.95	EPS next Y	56.40%	ROA	-44.50%	Target Price	-	Perf Year	1.81%
Cash/sh	1.64	P/C	4.47	EPS next 5Y	-	ROE	-251.50%	52W Range	5.91 - 11.52	Perf YTD	-9.41%
Dividend	-	P/FCF	-	EPS past 5Y	-1.90%	ROI	-63.20%	52W High	-36.46%	Beta	1.43
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	635.00%	Gross Margin	45.80%	52W Low	23.86%	ATR	0.31
Employees	182	Current Ratio	1.70	Sales Q/Q	1249.70%	Oper. Margin	-77.30%	RSI (14)	57.77	Volatility	4.45% 4.34%
Optionable	Yes	Debt/Eq	1.65	EPS Q/Q	-9.40%	Profit Margin	-97.60%	Rel Volume	0.36	Prev Close	7.28
Shortable	Yes	LT Debt/Eq	1.62	Earnings	May 27 BMO	Payout	-	Avg Volume	291.33K	Price	7.32
Recom	1.70	SMA20	5.48%	SMA50	6.49%	SMA200	-12.06%	Volume	103,586	Change	0.55%

May-18-21

Initiated

H.C. Wainwright

Buy

$23

Sep-11-20

Initiated

BTIG Research

Buy

Jul-12-19

Upgrade

WBB Securities

Buy → Strong Buy

Mar-12-19

Upgrade

WBB Securities

Speculative Buy → Buy

Jan-26-18

Initiated

Nomura

Buy

$18

Oct-06-17

Initiated

Seaport Global Securities

Buy

$19

Oct-04-17

Reiterated

H.C. Wainwright

Buy

$33 → $36

Feb-24-17

Reiterated

FBR & Co.

Outperform

$36 → $25

Jul-27-16

Reiterated

FBR Capital

Outperform

$33 → $36

Sep-29-15

Initiated

Nomura

Buy

Jul-29-15

Reiterated

ROTH Capital

Buy

$30 → $31

Jun-17-15

Reiterated

H.C. Wainwright

Buy

$23 → $32

Jun-15-15

Reiterated

ROTH Capital

Buy

$27.50 → $30

Jun-09-21 07:00AM	RedHill Biopharma to Present at the BIO Digital International Convention PR Newswire
Jun-07-21 07:00AM	RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study PR Newswire
May-27-21 07:15PM	35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021 ACCESSWIRE
07:05AM	Strength Seen in Redhill Biopharma Ltd. (RDHL): Can Its 5.4% Jump Turn into More Strength? Zacks
07:00AM	RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights PR Newswire
06:45AM	RedHill Biopharma Ltd. to Host Earnings Call ACCESSWIRE
May-26-21 11:06AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential TipRanks +5.38%
07:12AM	RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 PR Newswire
07:00AM	RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 PR Newswire
May-25-21 08:00AM	RedHill's Novel Late-Stage Pills Hold Promise Against COVID-19 and its Variants Benzinga
May-24-21 07:00AM	RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 PR Newswire
May-21-21 12:15PM	RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021 PR Newswire
May-20-21 07:00AM	RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021 PR Newswire
Apr-11-21 06:15AM	Could These 2 Exciting COVID Stocks be 10-Baggers? Motley Fool
Apr-09-21 07:00AM	RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue PR Newswire +8.94%
Mar-25-21 09:15AM	RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals PR Newswire
Mar-22-21 07:00AM	RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland PR Newswire
Mar-18-21 08:18AM	Recap: Redhill Biopharma Q4 Earnings Benzinga -6.19%
Mar-11-21 07:00AM	RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021 PR Newswire +5.80%
Mar-05-21 07:00AM	RedHill to Present at Upcoming Conferences in March PR Newswire
Mar-04-21 12:10PM	RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares PR Newswire
Mar-02-21 09:06AM	ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date PR Newswire -15.49%
08:23AM	RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares PR Newswire
Mar-01-21 04:53PM	RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares PR Newswire
Feb-23-21 08:07AM	RedHill Biopharma Expands Opaganib Global COVID-19 Study To US Benzinga -13.29%
07:33AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
07:13AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
07:03AM	RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. PR Newswire
Feb-18-21 01:00PM	RedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204 Benzinga
07:00AM	RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 PR Newswire
Feb-17-21 07:00AM	RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 PR Newswire
Feb-11-21 06:55AM	4 Top COVID Stocks to Buy in February Motley Fool
Feb-09-21 07:00AM	RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences PR Newswire
Jan-29-21 07:45AM	The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO Benzinga
07:26AM	RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib PR Newswire
07:00AM	RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib PR Newswire
Jan-28-21 09:03AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
08:02AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
07:27AM	RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals PR Newswire
Jan-26-21 06:20AM	These 2 Coronavirus Stocks Could Soar in the First Half of 2021 Motley Fool +5.69%
Jan-14-21 02:13PM	RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering PR Newswire
Jan-12-21 12:56PM	Why RedHill Biopharma Stock Is Tanking Today Motley Fool -13.66%
08:51AM	RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million PR Newswire
Jan-11-21 04:35PM	RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire
07:00AM	RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire
07:00AM	RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D CNW Group
Jan-08-21 02:11PM	Government of Canada awards contract for inspection, repair and overhaul of service boats CNW Group
Jan-07-21 09:28AM	RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation Zacks +5.01%
Jan-06-21 07:00AM	RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease PR Newswire
Jan-04-21 09:41AM	RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study Zacks
Dec-31-20 09:38AM	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire -5.61%
09:30AM	RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire
Dec-28-20 11:28AM	Is the Options Market Predicting a Spike in RedHill Biopharma (RDHL) Stock? Zacks
Dec-22-20 07:00AM	RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire
Dec-15-20 11:42AM	RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model PR Newswire
09:30AM	RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model CNW Group
Dec-14-20 08:00AM	RedHill Biopharma Added to NASDAQ Biotechnology Index PR Newswire +5.20%
Dec-07-20 07:00AM	RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans PR Newswire
Nov-29-20 09:45PM	RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire
Nov-27-20 04:53PM	Do Hedge Funds Love RedHill Biopharma Ltd (RDHL)? Insider Monkey
11:32AM	RedHill (RDHL) Expands Opaganib Manufacturing Capacity in US Zacks
Nov-25-20 12:39PM	RedHill Biopharma Expands Their U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire
10:36AM	RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 PR Newswire
Nov-24-20 06:00PM	RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire
Nov-23-20 09:00AM	RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire
08:00AM	RedHill Biopharma to Present at Evercore ISI HealthCONx and Piper Sandler Healthcare Conferences PR Newswire
Nov-20-20 08:00AM	RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease PR Newswire
Nov-19-20 06:00PM	RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease PR Newswire +13.54%
07:21AM	RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib PR Newswire
07:00AM	RedHill Announces Unanimous DSMB Recommendation to Continue Phase 2/3 COVID-19 Study with Opaganib PR Newswire
Nov-18-20 06:00PM	RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks PR Newswire
12:16PM	RedHill (RDHL) to Begin Study on Second Coronavirus Candidate Zacks
Nov-17-20 10:11AM	RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study Zacks
08:21AM	RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease PR Newswire
07:00AM	RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2/3 Study in Symptomatic COVID-19 Disease PR Newswire
Nov-16-20 11:28AM	RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks PR Newswire
10:13AM	RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks PR Newswire
Nov-13-20 07:00AM	RedHill Biopharma to Present at German Equity Forum 2020 GlobeNewswire
Nov-12-20 07:00PM	RedHill Biopharma (RDHL) Q3 2020 Earnings Call Transcript Motley Fool
07:38AM	Recap: Redhill Biopharma Q3 Earnings Benzinga
07:00AM	RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth GlobeNewswire
06:45AM	RedHill Biopharma Ltd. to Host Earnings Call ACCESSWIRE
Nov-11-20 10:14AM	A Preview Of Redhill Biopharma's Earnings Benzinga
Nov-05-20 07:00AM	RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020 GlobeNewswire
Nov-04-20 10:30AM	RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination GlobeNewswire
Oct-26-20 09:00AM	RedHill Biopharma Presents New Data from Talicia®s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication GlobeNewswire
Oct-15-20 10:26AM	RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation Zacks
Oct-14-20 11:00AM	RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections GlobeNewswire
Oct-13-20 11:24AM	REFILE-Israel's Redhill Biopharma signs manufacturing deal for potential COVID-19 treatment Reuters
10:30AM	RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib GlobeNewswire
Oct-08-20 10:30AM	RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca GlobeNewswire
Oct-07-20 10:00AM	RedHill Biopharmas Opaganib COVID-19 Study Passes Second Independent Committee Review GlobeNewswire
Oct-06-20 07:00AM	RedHill Biopharma to Present at BIO Investor and BIO-Europe 2020 Virtual Conferences GlobeNewswire -8.16%
Sep-23-20 02:31PM	Veeva Systems Again Enlisted To Help A Covid-19 Treatment Study, Making It Stock Of The Day Investor's Business Daily
12:46PM	RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib Zacks
10:35AM	Veeva Systems Enlisted To Help In Study Of Possible Covid-19 Treatment Investor's Business Daily
10:25AM	Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19 TheStreet.com
06:46AM	RedHill Gets Brazils Nod For Covid-19 Study With Opaganib SmarterAnalyst
Sep-22-20 10:00AM	Brazil Approves RedHill Biopharmas Phase 2/3 COVID-19 Study with Opaganib GlobeNewswire
Sep-09-20 07:00AM	RedHill to Present at the Morgan Stanley Annual Global Healthcare Conference and Additional September Events GlobeNewswire +12.01%

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience